Hemotrial Un proyecto de SEHH

Ensayo clínico

AN OPEN-LABEL, MULTI-CENTER CONTROLLED CLINICAL TRIAL OF ECULIZUMAB IN ADULT PATIENTS WITH PLASMA THERAPY-RESISTANT ATYPICAL HEMOLYTIC-UREMIC SYNDROME (AHUS)ESTUDIO CLÍNICO ABIERTO, MULTICÉNTRICO, CONTROLADO DE ADMINISTRACIÓN DE ECULIZUMAB EN PACIENTES ADULTOS CON SÍNDROME HEMOLÍTICO URÉMICO ATÍPICO (SHUa) RESISTENTE A LA PLASMOTERAPIA

  • Guardar

  • Imprimir
  • << Volver

Resumen

2017-03-15 04:10:16
2008-006952-23
C08-002A
AN OPEN-LABEL, MULTI-CENTER CONTROLLED CLINICAL TRIAL OF ECULIZUMAB IN ADULT PATIENTS WITH PLASMA THERAPY-RESISTANT ATYPICAL HEMOLYTIC-UREMIC SYNDROME (AHUS)ESTUDIO CLÍNICO ABIERTO, MULTICÉNTRICO, CONTROLADO DE ADMINISTRACIÓN DE ECULIZUMAB EN PACIENTES ADULTOS CON SÍNDROME HEMOLÍTICO URÉMICO ATÍPICO (SHUa) RESISTENTE A LA PLASMOTERAPIA
C08-002A

PROMOTORES DEL ENSAYO
Nombre del promotor Organización Persona de contacto País
ALEXION PHARMACEUTICALS, INC. United States

Fármacos

  INFORMACIÓN DE FÁRMACOS USADOS:
  FÁRMACO 1:
Test SOLIRIS 300 mg concentrado para solución para perf
ALEXION EUROPE SAS
Concentrate for solution for infusion
Intravenous use

Detalles del Fármaco (Principio Activo):
h5G1.1-mAb ECULIZUMAB

Concentración del fármaco:
mg/ml milligram equal

10

Contenido del fármaco

No
Si

No
Information no disponible en EudraCT

No
Si

No
No

Information no disponible en EudraCT
No

No
No

No
  INFORMACIÓN DE PLACEBOS USADOS:

No hay placebos asignados al ensayo

Información General

Terapia Celular

Adult patients with plasma therapy-resistant Atypical Hemolytic-Uremic Syndrome (aHUS)Pacientes adultos con síndrome hemolítico urémico atípico (SHUa) resistente a la plasmoterapia

Assess the effect of eculizumab to reduce thrombotic microangiopathy (TMA) as indicated by thrombocytopenia as measured by platelet count change from baseline through the treatment period in patients with plasma therapy-resistant Atypical Hemolytic-Uremic Syndrome (aHUS).

• Evaluate additional efficacy endpoints such as the effect of eculizumab on:- TMA Intervention Rate (# PT and # Dialysis Events/Patient/Day) during the Treatment Period compared with the TMA Intervention Rate prior to the first dose of Investigational Product.- TMA-Event Free status defined as the absence of [1] decrease in platelet count of >25% from the Platelet Count Pre-PT Baseline Set-Point; [2] PT while the patient is receiving eculizumab, and [3] new dialysis for at least 12 weeks.- Key Hemolytic measures.- Quality of Life measures.- Renal function measures.- TMA Remission.• Characterize the overall safety and tolerability of eculizumab.• Describe the pharmacokinetics (PK) and pharmacodynamics (PD) of eculizumab in patients with aHUS.• Perform a series of exploratory efficacy analyses.

No


1. Male or female patients ?18 years of age who have been diagnosed with Atypical Hemolytic-Uremic Syndrome (aHUS). Patients may be newly diagnosed, experiencing a relapse of the disease, or having a post-transplant recurrence of the disease.2. Patients must exhibit a decrease in platelet count despite at least 4 Plasma Therapy (PT) treatments in the 1 week immediately prior to screening. At screening, platelet count must be < 150 x 10^9/L and at least 25% lower than the average of 3 platelet counts obtained during remission and at least 1 month apart over the 12 months prior to screening (designated the "average remission platelet count").3. If historical counts are not available, platelet count at screening must be < 75 x 10^9/L despite PT treatment administration of at least 4 PT treatments in the 1 week immediately prior to screening.4. Known complement regulatory protein genetic abnormality, i.e., a mutation in Complement Protein 3, factor H or associated factor, factor I, or membrane cofactor protein 1 (MCP-1) or known Factor B gain-of-function mutation, or known Anti-CFH antibody ("aHUS lesions").• Patients diagnosed with aHUS with any of these aHUS lesions are eligible and will be assigned to one of the following parallel categories during the treatment period of the trial:- (Category 1) Complement Protein 3 or factor H or factor I functional deficiency or abnormal factor interaction (C3/CFH/CFI FFP Group);- (Category 2) Factor B Gain of Function;- (Category 3) Anti-CFH Antibody (anti-CFH Group);- (Category 4) MCP-1 deficiency (MCP-1 Group);5. Patients diagnosed with HUS of the atypical type without documented complement regulatory protein genetic abnormality or known anti-CFH antibody are eligible if other etiologies of HUS have been ruled out as confirmed in the Exclusion Criteria (i.e., including Shiga-toxin negative, non-infectious, non-drug-exposure-related [e.g., cyclosporine]), no known HIV positivity, and anti-phospholipid antibody negative). Thrombotic thrombocytopenic purpura also must be ruled out (i.e., DAMTS-13 activity must be > 5%; see Exclusion Criteria). Patients meeting these conditions will be assigned to Category 5. In addition, these patients will undergo genetic testing to determine if a mutation can be identified. If a mutation is identified, the patient will be reassigned to the appropriate category.6. Lactate dehydrogenase (LDH) level ? ULN;7. Creatinine level ? ULN for age (patients requiring acute dialysis for acute renal failure also eligible).8. Sexually active women of childbearing potential must be practicing an effective, reliable and medically acceptable contraceptive regimen during the entire duration of the study, including the follow-up period.9. Able to give informed consent or consent from a legal guardian.10. Able and willing to comply with study procedures.

1. ADAMTS-13 inhibitor or deficiency (i.e., ADAMTS-13 activity <5%) as measured at the screening visit.2. Malignancy.3. Typical HUS (Shiga toxin +).4. Known HIV infection.5. Identified drug exposure-related HUS.6. Infection-related HUS.7. Renal function status requiring chronic dialysis (defined as dialysis on a regular basis as renal replacement therapy).8. Patients with a confirmed diagnosis of sepsis defined as positive blood cultures within 7 days of the screening visit and not treated with antibiotics to which the organism is sensitive.9. Presence or suspicion of active and untreated systemic bacterial infection that, in the opinion of the Investigator confounds an accurate diagnosis of aHUS or impedes the ability to manage the aHUS disease.10. Pregnancy or lactation.11. Unresolved meningococcal disease.12. Known Systemic Lupus Erythematosus (SLE) or antiphospholipid antibody positivity or syndrome.13. Any medical or psychological condition that, in the opinion of the investigator, could increase the patient's risk by participating in the study or confound the outcome of the study.14. Patients receiving IVIg or Rituximab therapy.15. Patients receiving other immunosuppressive therapies such as steroids, mTOR inhibitors or FK506 inhibitors are excluded unless: [1] part of a post-transplant anti rejection regime, [2] patient has confirmed anti-CFH antibody requiring immunosuppressive therapy and [3] dose of such medications have been unchanged for at least 4 weeks prior to the screening period.16. Patients receiving Erythrocyte stimulating agents (ESAs) unless already on a stable dose for at least 4 weeks prior to the screening period.17. Participation in any other investigational drug trial or exposure to other investigational agent, device, or procedures beginning 4 weeks prior to screening and throughout the entire trial.

Platelet count change from baseline (Platelet Count Pre-PT Baseline Set-point value) after first dose of Investigational Product.

Fase II
  DISEÑO DEL ENSAYO:

Si
No

Si
No

No
No

No
Si
  COMPARADOR DEL ENSAYO CONTROLADO:

No
No

Si
No

Si

Centros participantes:

Si
Information no disponible en EudraCT
  TIEMPO ESTIMADO DURACIÓN DEL ENSAYO:

1
0
  TIEMPO ESTIMADO DURACIÓN DEL ENSAYO EN ESPAÑA:


  POBLACIÓN DE PACIENTES EN EL ESTUDIO:
  Población de pacientes: 1

Rango de edad:

0
1

1

Sexo:

1
1

Número planeado de pacientes a incluir:

3

Para estudios internacionales:

4
8

Investigadores

  INVESTIGADORES QUE PARTICIPAN EN EL ESTUDIO

Estado actual


 EC Finalizado



EC Finalizado